Clinical Trial

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-21.
Status change: Not Yet Recruiting → Recruiting 2026-05-19
Trial Details
NCT Number NCT07263594
Lead Sponsor DualityBio Inc.
Collaborators: GlaxoSmithKline
Conditions Gastrointestinal Cancer
Enrollment 127 participants
Start Date 2026-01-20
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22